Axsome Therapeutics, Inc. (AXSM) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
AXSM Insider Trading Activity
AXSM Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $8,356,810 | 7 | 100 |
Related Transactions
| Coleman Mark | director | 0 | $0 | 2 | $789,107 | $-789,107 |
| Saad Mark E | director | 0 | $0 | 1 | $1.01M | $-1.01M |
| Pizzie Nick | Chief Financial Officer | 0 | $0 | 2 | $1.95M | $-1.95M |
| Jacobson Mark L. | Chief Operating Officer | 0 | $0 | 2 | $4.61M | $-4.61M |
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Insider Activity of Axsome Therapeutics, Inc.
Over the last 12 months, insiders at Axsome Therapeutics, Inc. have bought $0 and sold $8.36M worth of Axsome Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Axsome Therapeutics, Inc. have bought $242,389 and sold $6.92M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,950 shares for transaction amount of $147,350 was made by JEFFS ROGER (director) on 2021‑11‑19.
List of Insider Buy and Sell Transactions, Axsome Therapeutics, Inc.
| 2025-02-14 | Sale | Pizzie Nick | Chief Financial Officer | 3,000 0.0062% | $131.07 | $393,210 | -10.35% | |
| 2025-02-13 | Sale | Pizzie Nick | Chief Financial Officer | 12,000 0.0244% | $129.86 | $1.56M | -9.99% | |
| 2024-09-11 | Sale | Saad Mark E | director | 11,016 0.0226% | $91.31 | $1.01M | +8.21% | |
| 2024-08-09 | Sale | Jacobson Mark L. | Chief Operating Officer | 47,739 0.1009% | $84.26 | $4.02M | +15.75% | |
| 2024-05-29 | Sale | Coleman Mark | director | 5,248 0.011% | $75.14 | $394,333 | +21.99% | |
| 2024-05-29 | Sale | Jacobson Mark L. | Chief Operating Officer | 7,910 0.0165% | $74.31 | $587,813 | +21.99% | |
| 2024-05-28 | Sale | Coleman Mark | director | 5,249 0.0108% | $75.21 | $394,775 | +19.40% | |
| 2024-04-01 | Sale | Jacobson Mark L. | Chief Operating Officer | 24,662 0.0522% | $77.24 | $1.9M | +15.39% | |
| 2024-03-15 | Sale | JEFFS ROGER | director | 2,347 0.0047% | $71.61 | $168,062 | +15.50% | |
| 2024-03-14 | Sale | JEFFS ROGER | director | 16,976 0.036% | $69.70 | $1.18M | +25.01% | |
| 2023-09-15 | Sale | Coleman Mark | director | 29,588 0.0626% | $75.18 | $2.22M | +1.06% | |
| 2021-11-19 | JEFFS ROGER | director | 3,950 0.0109% | $37.30 | $147,350 | +3.44% | ||
| 2021-11-18 | Coleman Mark | director | 1,430 0.0037% | $35.09 | $50,181 | +4.03% | ||
| 2021-11-18 | Pizzie Nick | CHIEF FINANCIAL OFFICER | 955 0.0025% | $35.26 | $33,676 | +4.03% | ||
| 2021-11-17 | Saad Mark E | director | 3,300 0.0087% | $34.52 | $113,922 | +7.00% | ||
| 2021-05-12 | Coleman Mark | director | 500 0.0014% | $58.15 | $29,075 | -38.38% | ||
| 2020-06-29 | Coleman Mark | director | 650 0.0018% | $78.50 | $51,025 | -5.10% | ||
| 2020-06-29 | Pizzie Nick | Chief Financial Officer | 777 0.0021% | $76.64 | $59,549 | -5.10% | ||
| 2019-09-26 | Pizzie Nick | Chief Financial Officer | 2,180 0.0063% | $24.80 | $54,064 | +210.19% | ||
| 2019-06-26 | Coleman Mark | director | 15,800 0.0481% | $23.10 | $364,980 | +145.30% |
Insider Historical Profitability
| Pizzie Nick | Chief Financial Officer | 42187 0.0857% | $4.46M | 6 | 2 | +84.72% |
| Coleman Mark | director | 14600 0.0297% | $1.54M | 7 | 3 | +51.01% |
| Saad Mark E | director | 10002 0.0203% | $1.06M | 2 | 1 | +23.86% |
| Jacobson Mark L. | Chief Operating Officer | 5783 0.0117% | $611,089.61 | 0 | 3 | |
| JEFFS ROGER | director | 120756 0.2453% | $12.76M | 1 | 2 | +3.44% |
| Kaye Randall | Chief Medical Officer | 6022 0.0122% | $636,344.74 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$159,914,414 | 243 | 18.52% | $7.49B | |
$211,610,344 | 91 | 38.45% | $6.56B | |
$52,263,649 | 70 | 1.18% | $4.75B | |
$108,876,545 | 67 | 72.81% | $6.19B | |
$88,307,390 | 38 | -1.70% | $6.34B | |
$62,927,079 | 29 | 14.02% | $3.75B | |
$415,105,240 | 19 | -14.04% | $6.32B | |
$11,859,102 | 17 | 18.62% | $3.66B | |
Axsome Therapeutics, Inc. (AXSM) | $1,279,017 | 16 | 51.12% | $5.2B |
$83,065,496 | 16 | 9.40% | $7.44B | |
$57,686,748 | 13 | 21.11% | $3.68B | |
$2,477,801 | 11 | 4.98% | $5.09B | |
$11,898,979 | 10 | 54.58% | $3.89B | |
$103,741 | 9 | 49.60% | $5.18B | |
$2,246,813 | 6 | 70.15% | $5.3B | |
$105,414,951 | 5 | 10.07% | $5.13B | |
$4,849,105 | 4 | 2.71% | $6.42B | |
$41,376,000 | 4 | -12.07% | $3.88B | |
$6,678,053 | 3 | 30.56% | $5.75B |
AXSM Institutional Investors: Active Positions
| Increased Positions | 167 | +49.26% | 6M | +16.22% |
| Decreased Positions | 145 | -42.77% | 6M | -15.01% |
| New Positions | 73 | New | 2M | New |
| Sold Out Positions | 34 | Sold Out | 2M | Sold Out |
| Total Postitions | 361 | +6.49% | 39M | +1.21% |
AXSM Ownership Change vs Market
Institutional Investor Ownership
| Rtw Investments, Lp | $454,604.00 | 8.27% | 4.05M | -138,192 | -3.3% | 2024-12-31 |
| Vanguard Group Inc | $437,897.00 | 7.96% | 3.9M | -92,866 | -2.32% | 2024-12-31 |
| Blackrock, Inc. | $395,474.00 | 7.19% | 3.52M | -8,983 | -0.25% | 2025-03-31 |
| Fairmount Funds Management Llc | $164,835.00 | 3% | 1.47M | -891,094 | -37.76% | 2024-12-31 |
| Bvf Inc/Il | $155,755.00 | 2.83% | 1.39M | +342,064 | +32.7% | 2024-12-31 |
| Fmr Llc | $112,260.00 | 2.04% | 1M | -87,641 | -8.05% | 2024-12-31 |
| Ra Capital Management, L.P. | $112,210.00 | 2.04% | 1M | 0 | 0% | 2024-12-31 |
| Macquarie Group Ltd | $108,176.00 | 1.97% | 964,047 | -31,240 | -3.14% | 2024-12-31 |
| State Street Corp | $106,291.00 | 1.93% | 947,251 | +30,443 | +3.32% | 2024-12-31 |
| Geode Capital Management, Llc | $102,396.00 | 1.86% | 912,538 | +4,079 | +0.45% | 2024-12-31 |